| 11.23.21 | GSK targets NASH with $1B Arrowhead pact; AZ's new R&D site, after long delay, finally opens

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

3 jahre vor

Html
Text

Founder-led biotechs leading the way

Webinar: A Systems Model of Gene Therapy for Sickle Cell Disease

Tuesday, November 30 | 2pm ET / 11am PT

Stem cell gene therapy is an emerging experimental therapy for SCD with the potential for lifelong cure but it is an expensive multi-step treatment regimen. This webinar is ideal for scientists and decision makers in drug R&D who want to leverage systems pharmacology for drug discovery and development. Register Now.

Today's Rundown

GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead AstraZeneca, after years of delays and spiraling costs, opens Cambridge R&D site. Will the bet pay off? Founder-led biotech is making space for ideas—and diverse leaders—where it didn't exist before Sponsored: Cross-Functional Strategies For the Development and Launch of New Products Vaccibody, now Nykode, celebrates new name with a Regeneron deal worth $900M-plus Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO UK launches review of racial, gender biases in medical devices, sparked by disproportionate COVID deaths Novartis may have a buyer for $21B generics unit Sandoz: report Major insurers won't pay for Biogen's Alzheimer’s drug until they get more proof that it works: Bloomberg survey

Featured Story

GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead

By Ben Adams

GlaxoSmithKline is making its first major foray into treating the fatty liver condition known as NASH as it pens a $1 billion asset pact with Arrowhead Pharmaceuticals.

This week's sponsor is New Product Planning.

AstraZeneca, after years of delays and spiraling costs, opens Cambridge R&D site. Will the bet pay off?

By Nick Paul Taylor

Five years late and 200% over budget, AstraZeneca has finally formally unveiled the Cambridge, U.K., site that is at the heart of its R&D strategy.

Founder-led biotech is making space for ideas—and diverse leaders—where it didn't exist before

By Annalee Armstrong

Reshma Shetty is part of a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. These scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

Vaccibody, now Nykode, celebrates new name with a Regeneron deal worth $900M-plus

By Ben Adams

Norwegian vaccine and immunotherapy biotech Vaccibody has changed its name to Nykode Therapeutics to “signify a new phase of growth and development,” and it started that phase with more than just PR speak.

Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO

By Nick Paul Taylor

Rafael Holdings is clearing out its C-suite. Weeks after the failure of its lead cancer drug, Rafael has disclosed the planned departures of five executives as it adapts to life without a near-approval asset.

UK launches review of racial, gender biases in medical devices, sparked by disproportionate COVID deaths

By Andrea Park

Racial and gender biases in medical devices are "totally unacceptable," said Sajid Javid, the U.K.’s secretary of state for health and social care.

Novartis may have a buyer for $21B generics unit Sandoz: report

By Kevin Dunleavy

Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase Novartis' generics unit Sandoz for $21.6 billion, according to German newspaper Handelsblatt. The price would make it the largest pharma deal of the year.

Major insurers won't pay for Biogen's Alzheimer’s drug until they get more proof that it works: Bloomberg survey

By Robert King

A Bloomberg survey of 25 major insurers found that none of the payers believe it's medically necessary to cover a controversial Alzheimer's drug made by Biogen.